Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial (NCT01597557), a randomized na study. The primary outcome is Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm.

2. Clinical Question

The primary endpoint is a participant count for a binary outcome: each participant either met the stated definition of success or did not. The registry’s description requires both conversion to sinus rhythm and maintenance of sinus rhythm for one hour; conversion alone does not meet that definition. The clinical question therefore concerns successful rhythm conversion sustained for the stated interval, not simply whether a cardioversion procedure was attempted.

The comparison is between magnesium sulfate and placebo administered before cardioversion. The registry describes a randomized, parallel-group trial with quadruple masking. It does not report further detail about how the masking was maintained or which roles were masked. The posted primary outcome counts show successes in both arms, and the statistical interpretation concerns the uncertainty around the difference between those observed counts. These results do not, by themselves, explain the mechanisms behind any outcome or establish what would occur in settings beyond the trial.

3. Trial Design

The registry record describes a randomized, parallel-group trial comparing intravenous magnesium sulfate with placebo in patients undergoing cardioversion for atrial fibrillation. It lists the study as completed and reports enrollment of 261. The recorded start is 2012-04, and the primary completion date is 2014-02. The phase is listed as NA.

Participants assigned to the magnesium sulfate arm received a 2-gram intravenous drip before the cardioversion procedure. Participants assigned to the placebo arm received a normal saline drip intravenously before the procedure. The registry identifies the masking as quadruple. That label indicates the masking category recorded in the registry; the specific people masked, the procedures used to preserve masking, and whether masking was assessed are not reported in the registry record.

The parallel design compares outcomes between the assigned arms. The primary result is presented as the number of participants with successful cardioversion, with arm-specific denominators. The registry defines success as conversion of atrial fibrillation to sinus rhythm and maintenance of sinus rhythm for one hour. It also lists total energy required for successful cardioversion and the number of participants experiencing severe hypotensive episodes after infusion among the secondary outcomes.

The registry record does not report the original sample-size justification, the planned analysis populations, or a detailed statistical analysis plan. It lists no reported analyses. Details such as allocation concealment, recruitment sites, eligibility criteria, participant characteristics, adherence, withdrawals, and missing outcome handling are not reported in the registry record. The trial’s posted outcome summaries can therefore be read as arm-level descriptions and comparisons, but the registry does not give enough information to reconstruct every aspect of the conduct or analysis.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Some patients enrolled in the study and received the study drug but did not undergo the cardioversion procedure due to various reasons

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm, measured over One hour after cardioversion.

The primary endpoint counts participants whose atrial fibrillation converted to sinus rhythm and whose sinus rhythm was maintained for one hour after cardioversion. It is a binary endpoint at the participant level: the registry’s definition distinguishes participants meeting the full success criterion from those who do not. The endpoint is not a measure of the duration of sinus rhythm beyond the stated interval.

This outcome is relevant to the stated clinical question because the trial was designed to evaluate whether magnesium sulfate could facilitate successful cardioversion. A count of participants meeting a prespecified success definition gives a direct comparison of the proportion achieving that outcome in each randomized arm. The registry reports 114 successful outcomes among 132 participants in the magnesium sulfate arm and 111 among 129 in the placebo arm.

The endpoint definition matters when interpreting the result. A rhythm conversion that was not maintained for the stated hour would not satisfy the registry’s definition of success. The record does not report further details about how rhythm was assessed, how participants with incomplete follow-up were classified, or how missing endpoint data were handled. The result should therefore be understood as the posted count-based endpoint under the registry definition, rather than as a broader measure of long-term rhythm control or other clinical outcomes.

7. Results Posted in the Registry

• Magnesium Sulfate: 86.4% (114/132) versus 86.0% (111/129) on control; risk difference 0.3 percentage points (95% CI -8.1 to 8.7), risk ratio 1.00 (0.91–1.11); unadjusted two-proportion z-test p = 0.941.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Total Amount of Energy Required for Successful Cardioversion of the Atrial Fibrillation to Sinus Rhythm

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Magnesium Sulfate: mean 123.30 versus 129.50 on control; difference -6.20 (95% CI -19.44 to 7.04), standardized effect d = -0.11; z-test p = 0.359.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Magnesium Sulfate and the control. The interval gives the range of effects that remain compatible with the data.

The registry names two secondary outcomes: the total energy required for successful cardioversion and the number of participants who experienced severe hypotensive episodes after infusion. A posted comparative summary is available for the energy outcome. The specific hypotensive-episode outcome does not have a separately reported result in the registry record. The broad adverse-event counts are not a substitute for a detailed result for that named endpoint.

The energy comparison does not provide a clearly separated result from the primary binary endpoint: its confidence interval includes no difference, and its unadjusted p-value is 0.359. This secondary finding should be viewed as complementary information about the procedure, not as a replacement for the primary question about maintained sinus rhythm. Nor does the pattern across these endpoints establish a consistent beneficial or harmful effect. The outcomes measure different things and have different scales.

Secondary results generally carry less weight than a prespecified primary result because they may be numerous, may not be powered for definitive inference, and may be subject to selective emphasis. When several outcomes are tested, unadjusted p-values do not account for the increased chance of a chance finding across the outcome set. The registry does not report a multiplicity plan, a hierarchy among outcomes, or reported analyses. Accordingly, the secondary summaries are useful for describing what was measured, but they should be interpreted cautiously and in the context of the primary result and the limitations of the registry record.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Total Amount of Energy Required for Successful Cardioversion of the Atrial Fibrillation to Sinus Rhythm
• Number of Participants Who Experienced Severe Hypotensive Episodes After Infusion of Magnesium Sulfate or Placebo

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is binary because the registry classifies participants according to whether they met the success definition. For a binary outcome, an arm-specific event proportion is the number meeting the definition divided by the number in that arm. The posted counts are 114 of 132 for magnesium sulfate and 111 of 129 for placebo. A comparison can be expressed as an absolute difference in proportions or as a relative measure, such as a risk ratio or odds ratio. Each expresses the contrast on a different scale.

What does the risk difference express?

The risk difference is the proportion with the outcome in one arm minus the proportion in the comparator arm, according to the comparison’s stated direction. A value at zero represents equal proportions. Positive or negative values indicate the direction of the contrast under that coding. The posted estimate is close to zero, and its confidence interval crosses zero. That interval is compatible with effects in either direction; it does not support a precise claim that the underlying difference is exactly zero.

Why are relative measures also reported?

A risk ratio compares the outcome proportions as a ratio, while an odds ratio compares the odds of the outcome. Their no-effect reference is one, rather than zero. Values on either side of that reference indicate different directions of association. The posted relative-effect intervals include the no-effect reference. These metrics can make an effect look different depending on the scale, so interpretation should remain tied to the clinical outcome and the underlying arm counts. They are alternative descriptions of the same data, not separate trials or independent evidence.

What does a confidence interval tell the reader?

A confidence interval summarizes uncertainty around an estimate under the assumptions of the method used to construct it. In repeated use of the same procedure, intervals would cover the underlying quantity at the stated confidence level at the corresponding long-run rate. For an individual study, it is not correct to interpret the interval as assigning a probability that the fixed true effect lies within that particular interval. Its practical value is that it shows a range of effects compatible with the data and method, making precision visible alongside the point estimate.

What does the unadjusted p-value mean?

A p-value measures how incompatible the observed data, or data more extreme, are with a specified null hypothesis under the model used for the test. It is not the probability that the null hypothesis is true, nor does it measure the size or clinical importance of an effect. The primary outcome’s unadjusted p-value is 0.941. The registry does not identify the precise test or model behind that value, so it should not be used to infer an undocumented analysis procedure. It is described as unadjusted, and the registry lists no reported analyses.

The secondary continuous endpoint reports arm means and standard deviations. A mean summarizes the average energy requirement among the participants represented in each arm’s result. A standard deviation describes the spread of individual observations around the arm mean; it is not a confidence interval for the mean. The mean difference compares the arm averages. Its posted confidence interval includes zero, meaning the summary does not sharply distinguish a lower mean from no difference or a higher mean under the reported comparison.

In general, a mean comparison can be sensitive to the shape of the outcome distribution and to unusual values. A normal approximation may be used in some methods, but the registry does not report the analysis method for the trial’s energy endpoint. The sample-size illustration separately states a normal approximation for its planning calculations; that assumption should not be mistaken for confirmation of the original trial’s analysis method.

Why do unadjusted secondary findings need caution?

When investigators examine several outcomes, the chance of finding at least one apparently notable result can rise if each is tested separately without accounting for the set of tests. A multiplicity procedure can control or otherwise address that issue, depending on the prespecified objective. No multiplicity adjustment or outcome hierarchy is reported in the registry record. Thus the unadjusted secondary p-value is best treated as a descriptive statistical summary, not as definitive evidence considered independently of all the other outcomes.

Statistical significance is also distinct from importance. A small p-value does not say whether an effect matters clinically, and a larger p-value does not prove the absence of an effect. Estimation, confidence intervals, endpoint definitions, study conduct, and the prespecified analysis all contribute to interpretation. In this record, important details about the original statistical plan, missing data, analysis populations, and adjustment are not reported. The posted numerical results can be described, but those missing details limit how fully the inferential analysis can be audited.

11. Confidence Intervals and Precision

The primary risk-difference estimate is close to zero, but its confidence interval spans zero and extends in both directions. This means the result is not very precise about the direction of the underlying difference: values favoring either arm remain compatible with the posted interval. The interval is the key complement to the point estimate. The unadjusted p-value of 0.941 alone cannot show the range of effect sizes that remain plausible under the reported method.

The relative-effect confidence intervals also include their no-effect reference. This reinforces that the posted binary-outcome summaries do not isolate a single direction of effect. The registry gives relative estimates on risk-ratio and odds-ratio scales, but those measures should be read alongside the arm counts and absolute comparison. Because the lower confidence bounds for some relative measures are reported with more than three decimal places, they are not repeated in this discussion.

For energy required, the posted mean difference is -6.2 Joules and its confidence interval crosses zero. The interval therefore does not precisely distinguish a lower energy mean from no difference or a higher mean. The unadjusted p-value of 0.359 is consistent with the lack of a sharp distinction, but the interval is more informative about the range and direction of uncertainty.

In general, a wide interval indicates that the data leave substantial uncertainty about the effect size, while a narrow interval gives a more precise estimate. Precision is not the same as absence of bias: confidence intervals do not account for every possible problem in study conduct or reporting. The registry does not report missing-data methods, the analysis population, or the procedures used to calculate the intervals, so their interpretation depends on assumptions that cannot be fully assessed from the record alone.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size illustrations are planning calculations, not a description of the trial’s original design justification. For these outcomes, the figures are participants per arm; the planning information says that only time-to-event illustrations are expressed as total events, and the outcomes in this trial are not time-to-event outcomes. The original trial’s own sample-size assumptions are not reported in the registry record.

The illustration uses a two-sided significance level of 0.05, equal allocation between the arms, and a normal approximation. It sets the effect to detect as a stated fraction of the observed effect. The rows therefore represent planning for 100% of the observed effect, 75% of the observed effect, and 50% of the observed effect. The 80% power column gives the planned participants per arm for a design with an 80% chance of detecting the specified effect under those assumptions, if that effect were the true one. The 90% power column has the corresponding interpretation for a 90% chance.

The calculations illustrate that smaller effects require more participants to detect under otherwise unchanged assumptions. For the binary outcome, the observed effect is very close to zero, so planning around fractions of that observed estimate yields very large per-arm figures. The energy endpoint has a separate planning illustration based on its observed mean difference. These figures are hypothetical design illustrations, not evidence that the completed trial had a particular probability of detecting an effect. They are not observed power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.860; treatment proportion p₁ = 0.864; average p̄ = 0.862.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.4877 = 0.9558.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.4877 = 0.4104.
4. n = (0.9558 + 0.4104)² / (0.0032)² = 185,620.9, rounded up to 185,621 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.86046511627907                          # control proportion
p1 <- 0.863636363636364                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(1597557)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 185,621 (80% power), 248,494 (90% power)
 75% of observed effect: n per arm = 330,790 (80% power), 442,834 (90% power)
 50% of observed effect: n per arm = 746,068 (80% power), 998,773 (90% power)
power.prop.test: 185620.9 
Simulated power at n = 185,621 per arm: 0.799 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary outcome and secondary outcomes, but it does not report a prespecified hierarchy among them or a method for controlling multiplicity. When several outcomes are examined, separate unadjusted tests can increase the chance of at least one result appearing unusual by chance. There are statistical approaches to address this issue, but the record does not say whether any were planned or used. The posted p-values are therefore described as unadjusted and should not be treated as if a multiplicity correction had been applied.

The registry lists no reported analyses. It does not identify the statistical test for the primary binary outcome, the model or covariates for any adjusted analysis, or whether the reported comparisons follow an intention-to-treat, per-protocol, or other analysis population. Those analysis-population definitions are not reported in the registry record. The available counts and denominators describe the posted outcome summaries, but do not by themselves establish which participants were included under a prespecified analysis rule.

Missing-data handling is also not reported in the registry record. The record does not explain whether outcomes were missing, how missing outcomes were classified, or whether any sensitivity analysis was conducted. It would be inappropriate to assume that every randomized participant had complete outcome data or that a particular imputation or exclusion method was used. The same limitation applies to withdrawals and deviations from the assigned intervention: their handling is not described in the posted record.

These gaps do not change the arithmetic of the posted summaries, but they limit assessment of how robustly the estimates answer the intended question. A complete statistical plan and transparent accounting of outcome availability and analysis populations would help readers judge potential bias and the role of chance. Without those details, interpretation should remain focused on the reported counts, estimates, and their uncertainty, while recognizing that important analytic decisions are not documented.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event summary lists zero serious adverse events and zero other adverse events in the magnesium sulfate arm, with 132 participants at risk in each category. It also lists zero serious adverse events and zero other adverse events in the placebo arm, with 129 participants at risk in each category. These are the registry’s broad event counts.

The record lists no serious adverse-event terms and does not provide a separate detailed account of event types, timing, severity criteria, or relatedness assessments. A zero count in the posted summary should therefore be read as no events recorded in that category in this registry summary, not as proof that no event of any kind occurred or that all safety concerns were excluded.

Severe hypotensive episodes after infusion are named as a secondary outcome, but a distinct result for that specific outcome is not reported in the registry record. The broad adverse-event figures should not be substituted for that endpoint. Death counts are not reported in the adverse-event summary, so they cannot be interpreted as zero.

16. What the Result Does, and Does Not, Mean

The posted primary outcome counts show successful cardioversion, as defined by conversion to sinus rhythm maintained for one hour, in both arms. The estimated contrast is close to zero, the confidence interval includes no difference and effects in either direction, and the unadjusted p-value is 0.941. These results do not show a clear difference in the posted data. They also do not prove that the interventions have identical effects or rule out every potentially meaningful effect.

The energy outcome offers a secondary measure of the cardioversion procedure. Its reported mean difference is -6.2 Joules, but the confidence interval includes zero and the unadjusted p-value is 0.359. This summary does not precisely establish the direction or magnitude of a difference. The registry does not separately report the named severe hypotensive-episode outcome, and the available broad adverse-event counts cannot answer that specific question.

These findings apply to the participants and procedures represented in this completed trial, as described in the registry. The record does not provide detailed participant characteristics, eligibility criteria, site information, or enough procedural detail to judge how closely the trial resembles other clinical settings. It also does not report the original statistical plan, analysis populations, or missing-data methods. Those omissions constrain both reproducibility and assessment of the assumptions behind the comparisons.

Statistical evidence and clinical importance are related but distinct. An estimate describes the direction and size of an observed contrast; its uncertainty describes how much the data leave unresolved. A p-value does not measure clinical benefit, and failure to find a clear difference is not proof of equivalence. The results should be read as an account of the posted trial summaries, not as medical advice or a conclusion that either intervention should or should not be used.

17. Why This Trial Matters Statistically

This trial illustrates why arm-level counts and uncertainty need to be read together. The primary outcome is straightforward to define as a participant-level success, yet the inferential question is not answered by comparing the raw counts alone. The denominators differ, and the posted risk-difference estimate and confidence interval express the comparison while making uncertainty visible. The interval crossing zero means that the observed similarity does not establish exact equivalence.

The record also shows why separate outcome types should not be collapsed into one conclusion. Successful maintenance of sinus rhythm is a binary endpoint, whereas energy requirement is continuous and describes a procedural quantity. The outcomes address related but distinct questions, and the registry does not report the specific severe hypotensive-episode result. Readers need to distinguish what was measured from what the posted data can support.

Several key statistical safeguards are not documented: the original design assumptions, analysis populations, missing-data handling, and multiplicity strategy. Their absence does not invalidate the reported numbers, but it limits how completely readers can evaluate the inferential framework. This is a useful example of how a completed randomized trial record can provide outcome summaries while leaving important details needed for a full statistical audit unreported.

The planning illustrations also demonstrate a general point: required sample size depends on the effect a study aims to detect, the desired power, and the planning assumptions. Calculations based on an observed effect are not a retrospective measure of the trial’s power and are not evidence about whether the trial was adequately designed. Keeping those distinctions clear helps prevent overinterpretation of both nonsignificant results and planning figures.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record gives limited information about trial conduct and participant characteristics. It does not report the eligibility criteria, baseline characteristics, recruitment sites, allocation concealment, or details about which people were masked. The masking category is recorded as quadruple, but the practical procedures used to maintain it are not described. These gaps make it difficult to assess generalizability and potential sources of bias from the registry alone.

The record also does not report the original sample-size justification or detailed statistical analysis plan. Although planning illustrations are available based on the observed effects, they are not the trial’s original design rationale. The registry lists no reported analyses, and does not specify the exact tests, analysis populations, covariate adjustment, missing-data approach, or handling of withdrawals and protocol deviations. Those details matter for judging whether the posted comparisons match the intended analysis.

Outcome reporting is incomplete for some questions. The registry names severe hypotensive episodes as a secondary outcome, but does not report a separate result for it. Broad adverse-event counts are listed, while event details and death counts are not. The energy outcome has a comparative summary, but its analysis method is not described in the registry record.

The primary endpoint is limited to maintenance of sinus rhythm for one hour after cardioversion. The registry does not establish outcomes beyond that interval. The reported results therefore should not be extended to longer-term rhythm outcomes or other effects not described in the record. These limitations apply to interpretation of the registry summaries and do not imply that unreported procedures or analyses were absent; they are simply not reported in the registry record.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial — NCT01597557.
• Registry record last updated 2020-10-22; status last verified 2020-09.
• Results first posted 2020-10-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry record describes a completed randomized, parallel-group, quadruple-masked comparison of intravenous magnesium sulfate and normal saline placebo before cardioversion for atrial fibrillation. Enrollment was 261. The magnesium sulfate arm received 2 grams intravenously before the procedure.

The primary endpoint was successful conversion to sinus rhythm maintained for one hour. The posted counts were 114 of 132 in the magnesium sulfate arm and 111 of 129 in the placebo arm. The risk-difference confidence interval crosses zero, and the unadjusted p-value is 0.941. The secondary energy outcome has a posted mean difference of -6.2 Joules, with a confidence interval crossing zero and an unadjusted p-value of 0.359. A separate result for the named severe hypotensive-episode outcome is not reported in the registry record.

The record does not report the original sample-size justification, analysis populations, missing-data methods, multiplicity plan, or detailed statistical analysis plan. The findings should therefore be understood as the posted outcome summaries, with the uncertainty and reporting limitations.